Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: Studies in vivo, ex vivo, and in vitro

Hypertension

Volumn 63, Issue 4, 2014, Pages 774-782

  Haber, Philipp K ^a,b   Ye, Minghao ^a   Wysocki, Jan ^a   Maier, Christoph ^a,b   Haque, Syed K ^a   Batlle, Daniel ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

1 ((2 dimethylamino) ethylamino) 4 (hydroxymethyl) 7 ((4 methylphenyl)sulfonyloxy) 9H xanthene 9 one; diminazene; hypertension; renin angiotensin system

Indexed keywords

(1 [(2 DIMETHYLAMINO)ETHYLAMINO] 4 (HYDROXYMETHYL) 7 [(4 METHYLPHENYL) SULFONYL OXY] 9H XANTHENE 9 ONE); ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; DIMINAZENE; ENZYME ACTIVATOR; GLUTAMYL AMINOPEPTIDASE; MLN 4760; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLOGICAL ACTIVITY; BLOOD PRESSURE; CONTROLLED STUDY; DEGRADATION; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; EX VIVO STUDY; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

1-((2-DIMETHYLAMINO)ETHYLAMINO)-4-(HYDROXYMETHYL)-7-((4-METHYLPHENYL)SULFONYLOXY)-9H-XANTHENE-9-ONE; DIMINAZENE; HYPERTENSION; RENIN-ANGIOTENSIN SYSTEM;

ANGIOTENSIN I; ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; DIMINAZENE; DISEASE MODELS, ANIMAL; GLUTAMYL AMINOPEPTIDASE; HYPERTENSION; IMIDAZOLES; KIDNEY; LEUCINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; RATS; XANTHONES;

EID: 84897030042     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.02856     Document Type: Article

References (40)

1. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ace2) converts angiotensin i to angiotensin 1-9. Circ Res. 2000;87:e1-e9.
2. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem. 2000;275:33238-33243.
3. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB, Diz DI. Counterregulatory actions of angiotensin-(1-7). Hypertension. 1997;30(3 Pt 2):535-541.
4. Harrison-Bernard LM, Chappell MC. Unraveling the glomerular RAS: one peptidase at a time. Am J Physiol Renal Physiol. 2012;303:F373-F374.
5. Chappell MC. Nonclassical renin-angiotensin system and renal function. Compr Physiol. 2012;2:2733-2752.
6. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.
7. Ingelfnger JR. ACE2: a new target for prevention of diabetic nephropa-thy? J Am Soc Nephrol. 2006;17:2957-2959.
8. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879.
9. Ye M, Wysocki J, Naaz P, Salabat MR, LaPointe MS, Batlle D. Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension. 2004;43:1120-1125.
10. Alghamri MS, Weir NM, Anstadt MP, Elased KM, Gurley SB, Morris M. Enhanced angiotensin II-induced cardiac and aortic remodeling in ACE2 knockout mice. J Cardiovasc Pharmacol Ther. 2013;18:138-151.
11. Batlle D, Wysocki J, Soler MJ, Ranganath K. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int. 2012;81:520-528.
12. Benter IF, Yousif MHM, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1-7) prevents activation of nadph oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am J Nephrol. 2008;28:25-33.
13. Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD. Effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol. 2010;298:F1523-F1532.
14. Gurley SB, Allred A, Le TH, Griffths R, Mao L, Philip N, Haystead TA, Donoghue M, Breitbart RE, Acton SL, Rockman HA, Coffman TM. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest. 2006;116:2218-2225.
15. Kuba K, Imai Y, Penninger JM. Multiple functions of angiotensin- converting enzyme 2 and its relevance in cardiovascular diseases. Circ J. 2013;77:301-308.
16. Raffai G, Durand MJ, Lombard JH. Acute and chronic angiotensin-(1-7) restores vasodilation and reduces oxidative stress in mesenteric arteries of salt-fed rats. Am J Physiol Heart Circ Physiol. 2011;301:H1341-H1352.
17. Rentzsch B, Todiras M, Iliescu R, Popova E, Campos LA, Oliveira ML, Baltatu OC, Santos RA, Bader M. Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function. Hypertension. 2008;52:967-973.
18. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, Cooper ME, Thomas MC. ACE2 defciency modifes renoprotection afforded by ACE inhibition in experimental diabetes. Diabetes. 2008;57:1018-1025.
19. Wysocki J, Ye M, Rodriguez E, González-Pacheco FR, Barrios C, Evora K, Schuster M, Loibner H, Brosnihan KB, Ferrario CM, Penninger JM, Batlle D. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension. 2010;55:90-98.
20. Ye M, Wysocki J, Gonzalez-Pacheco FR, Salem M, Evora K, Garcia-Halpin L, Poglitsch M, Schuster M, Batlle D. Murine recombi-nant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2. Hypertension. 2012;60:730-740.
21. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17:3067-3075.
22. Hernández Prada JA, Ferreira AJ, Katovich MJ, Shenoy V, Qi Y, Santos RA, Castellano RK, Lampkins AJ, Gubala V, Ostrov DA, Raizada MK. Structure-based identifcation of small-molecule angiotensin-converting enzyme 2 activators as novel antihypertensive agents. Hypertension. 2008;51:1312-1317.
23. Kulemina LV, Ostrov DA. Prediction of off-target effects on angiotensin-converting enzyme 2. J Biomol Screen. 2011;16:878-885.
24. Kuriakose S, Muleme HM, Onyilagha C, Singh R, Jia P, Uzonna JE. Diminazene aceturate (Berenil) modulates the host cellular and infammatory responses to Trypanosoma congolense infection. PLoS One. 2012;7:e48696.
25. Martins Lima A, Xavier CH, Ferreira AJ, Raizada MK, Wallukat G, Santos RAS, Fontes MAP. Activation of angiotensin-converting enzyme 2/angiotensin-(1-7)/mas axis attenuates the cardiac reactivity to acute emotional stress. American Am J Physiol Heart Circ Physiol. 2013;305:H1057- H1067.
26. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:1048-1054.
27. Rigatto K, Casali KR, Shenoy V, Katovich MJ, Raizada MK. Diminazene aceturate improves autonomic modulation in pulmonary hypertension. Eur J Pharmacol. 2013;713:89-93.
28. Shenoy V, Gjymishka A, Jarajapu YP, et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med. 2013;187:648-657.
29. Foureaux G, Nogueira JC, Nogueira BS, Fulgêncio GO, Menezes GB, Fernandes SO, Cardoso VN, Fernandes RS, Oliveira GP, Franca JR, Faraco AA, Raizada MK, Ferreira AJ. Antiglaucomatous effects of the activation of intrinsic Angiotensin-converting enzyme 2. Invest Ophthalmol Vis Sci. 2013;54:4296-4306.
30. Qi Y, Zhang J, Cole-Jeffrey CT, Shenoy V, Espejo A, Hanna M, Song C, Pepine CJ, Katovich MJ, Raizada MK. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension. 2013;62:746-752.
31. Ferreira AJ, Shenoy V, Qi Y, Fraga-Silva RA, Santos RA, Katovich MJ, Raizada MK. Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fbrosis involving extracellular signal-regulated kinases. Exp Physiol. 2011;96:287-294.
32. Fraga-Silva RA, Costa-Fraga FP, Murça TM, et al. Angiotensin-converting enzyme 2 activation improves endothelial function. Hypertension. 2013;61:1233-1238.
33. Fraga-Silva RA, Sorg BS, Wankhede M, Dedeugd C, Jun JY, Baker MB, Li Y, Castellano RK, Katovich MJ, Raizada MK, Ferreira AJ. ACE2 activation promotes antithrombotic activity. Mol Med. 2010;16:210-215.
34. Murça TM, Almeida TC, Raizada MK, Ferreira AJ. Chronic activation of endogenous angiotensin-converting enzyme 2 protects diabetic rats from cardiovascular autonomic dysfunction. Exp Physiol. 2012;97:699-709.
35. Murça TM, Moraes PL, Capuruço CA, Santos SH, Melo MB, Santos RA, Shenoy V, Katovich MJ, Raizada MK, Ferreira AJ. Oral administration of an angiotensin-converting enzyme 2 activator ameliorates diabetes-induced cardiac dysfunction. Regul Pept. 2012;177:107-115.
36. Feng M, Whitesall S, Zhang Y, Beibel M, Alecy LD, DiPetrillo K. Validation of volume-pressure recording tail-cuff blood pressure measurements. American J Hypertens. 2008;21:1288-1291.
37. Wysocki J, Garcia-Halpin L, Ye M, Maier C, Sowers K, Burns KD, Batlle D. Regulation of urinary ACE2 in diabetic mice. Am J Physiol Renal Physiol. 2013;305:F600-F611.
38. Poglitsch M, Domenig O, Schwager C, Stranner S, Peball B, Janzek E, Wagner B, Jungwirth H, Loibner H, Schuster M. Recombinant expression and characterization of human and murine ACE2: species-specifc activation of the alternative renin-angiotensin-system. Int J Hypertens. 2012;2012:428950.
39. Raij L. The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease. Am J Hypertens. 2005;18(4 Pt 2):95S-99S.
40. Shenoy V, Qi Y, Katovich MJ, Raizada MK. ACE2, a promising therapeutic target for pulmonary hypertension. Curr Opin Pharmacol. 2011;11:150-155.